07:00 Mon 01 Mar 2021
ReNeuron Group plc - Block Listing Review and Total Voting Rights
ReNeuron Group plc
("ReNeuron" or the "Company")
Block Listing Review and Total Voting Rights
ReNeuron Group plc (AIM: RENE), a
Name: |
ReNeuron Group plc |
Name of Scheme: |
ReNeuron Share Option Schemes |
Period of Return: |
From |
Balance of unallotted securities under scheme(s) from previous return: |
674,687 Ordinary Shares (of 1p each)
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for): |
N/A |
Less: Number of securities issued/allotted under scheme(s) during period |
11,000 |
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
663,687 Ordinary Shares |
Number and class of securities originally admitted and the date of admission: |
20,000 ordinary shares on |
Total Voting Rights
At
As the Company holds no ordinary shares in treasury, the figure of 56,855,705 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Contacts:
ReNeuron |
||
|
Via Walbrook PR |
|
|
|
|
|
|
|
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) |
+44 (0)20 7710 7600
|
|
|
|
|
Allenby Capital Limited (Joint Broker) |
+44 (0)20 3328 5656 |
|
|
|
|
|
|
|
|
|
|
Walbrook PR (Media & Investor Relations) |
+44 (0)20 7933 8780 or reneuron@walbrookpr.com |
|
|
+44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. he Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE